Journal Information
Vol. 34. Issue 4.
Pages 170-180 (January 2010)
Vol. 34. Issue 4.
Pages 170-180 (January 2010)
Original article
Full text access
Analysis of the budget impact for the Spanish National Health System of the fixed combination of amlodipine 5 or 10mg and atorvastatin 10mg
Análisis del impacto presupuestario para el Sistema Nacional de Salud de la combinación fija de amlodipino 5 o 10mg y atorvastatina 10mg
Visits
2449
M. De Salasa, J. Fernández De Bobadillab, B. Ferroc, J. Rejasc,
Corresponding author
Javier.rejas@pfizer.com

Corresponding author.
a Departamento de Investigación de Resultados en Salud y Farmacoeconomía, Trial Form Support, Madrid, Spain
b Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
c Unidad Médica, Departamento de Investigación de Resultados en Salud y Farmacoeconomía, Pfizer España, Alcobendas, Madrid, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Objective

To carry out a Budget Impact Analysis (BIA) of the inclusion of the administration of the fixed combination (FC) of amlodipine 5 or 10mg and atorvastatin 10mg for approved indications in the Spanish National Health System (SNHS).

Material and methods

A BIA was carried out from the SNHS perspective for a 3-year period (2009–2011). A tree-type decision model was designed (patient tree), based on epidemiological data and scientific literature, in order to estimate the hypertensive population that could be treated with the FC. The total per annum BIA was calculated by attributing the retail price+VAT of the FC to the number of patients to be treated, and deducting the cost of the treatment for hypertension that was replaced and the updated average cost per patient of cardiovascular events (CVEs) prevented by the use of the FC by the SNHS during the period of study.

Results

The patient population likely to be treated with the FC was 51,104 patients (1st year), with a growth rate of 1%–2% over the following years, which means an annual cost (€) of 15.9M (2009), 19.9M (2010) and 24.1M (2011), with a total of 60.0M. The BIA was compensated showing negative impact values for the SNHS when the cost of replaced antihypertensive treatment and prevented CVEs was deducted, with savings of 69.9M € over 3 years.

Conclusion

The BIA of a FC of atorvastatin and amlodipine shows that the use of this medication for approved indications could generate net savings for the SNHS of 9.9M € for the period 2009–2011.

Keywords:
Fixed combination of amlodipine/atorvastatin
Budget impact analysis
Hypertension
Economic model
Cardiovascular risk
Health costs
Resumen
Objetivo

Realizar un análisis de impacto presupuestario (AIP) de la introducción en la prestación sanitaria del sistema nacional de salud (SNS) de la combinación fija (CF) de amlodipino 5 o 10mg y atorvastatina 10mg en la indicación aprobada.

Material y métodos

El AIP se ha realizado desde la perspectiva del SNS para un periodo de 3 años (2009–2011). Se ha diseñado un modelo de decisión tipo árbol (árbol de pacientes) construido a partir de datos epidemiológicos y la literatura científica para estimar la población hipertensa susceptible de tratamiento con la CF. El AIP, por año y en total, se ha calculado imputando el coste a PVP-IVA de la CF al número de pacientes por tratar, del que se sustrae el coste del tratamiento antihipertensivo que se sustituye y el coste por paciente promedio actualizado de los eventos cardiovasculares prevenidos para el SNS por el uso de la CF en el periodo de referencia.

Resultados

La población susceptible de tratamiento con la CF es de 51.104 pacientes (1.er año), con una tasa de crecimiento entre 1–2% en los sucesivos años, lo que supone un coste (€) anual de 15,9M (2009), 19,9M (2010) y 24,1M (2011), totalizando 60,0M. El AIP se ve compensado mostrando valores de impacto negativo para el SNS cuando se descuentan los costes del tratamiento antihipertensivo sustituido y eventos cardiovasculares prevenidos, mostrando un ahorro de 69,9M € en 3 años.

Conclusión

El AIP de la CF de atorvastatina y amlodipino muestra que su uso en la indicación aprobada podría generar ahorros netos para el SNS en el periodo 2009–2011 de 9,9M €.

Palabras clave:
Combinación fija amlodipino/atorvastatina
Análisis de impacto presupuestario
Hipertension
Modelo económico
Riesgo cardiovascular
Costes sanitarios
Full text is only available in PDF
References
[1.]
L. Hansson, A. Zanchetti, S.G. Carruthers, W. Kuerrt, J.H. Koller, Z. Beneriont, on behalf of HOT Study Group, et al.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial.
Lancet, 351 (1998), pp. 1755-1762
[2.]
R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, et al.
Blood pressure, stroke and coronary disease Part 2, Short term term reductions in blood pressure: overview of randomized drug trials in their epidemiological context.
Lancet, 335 (1990), pp. 827-828
[3.]
R. Asmar, S. Vol, B. Pannier, A.M. Brisac, J. Tichet, A. El Hasnaoui.
High blood pressure and associated cardiovascular risk factors in France.
J Hypertens, 19 (2001), pp. 1727-1732
[4.]
F.A. Tremollieres, J.M. Pouilles, C. Caunielle, C. Ribot.
Coronary heart disease risk factors and menopause: a study in 1684 French women.
Atherosclerosis, 142 (1999), pp. 415-423
[5.]
F. Thomas, A. Rudnichi, A.M. Bacri, K. Bean, L. Guize, A. Benetos.
Cardiovascular mortality in hypertensive in men according to presence of associated risk factors.
Hypertension, 37 (2001), pp. 1256-1261
[6.]
R.M. Conroy, K. Pyörälä, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, on behalf of the SCORE Project Group, et al.
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
Eur Heart J, 24 (2003), pp. 903-987
[7.]
P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, ASCOT investigators, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[8.]
R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised, placebo-controlled trial.
[9.]
H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, et al.
CARDS investigatores Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
[10.]
N.J. Wald, M.R. Law.
A strategy to reduce cardiovascular disease by more than 80%.
[11.]
M.T. Olalla, M.J. Medrano, M.J. Sierra, J. Almazán.
Time trends, cohort effect and spatial distribution of cerebrovascular disease mortality in Spain.
Eur J Epidemiol, 15 (1999), pp. 331-339
[12.]
M.J. Barrado, M.J. Medrano, J. Almazán.
Mortalidad por cardiopatía isquémica en España: tendencia y distribución geográfica.
Rev Esp Cardiol, 48 (1995), pp. 106-114
[13.]
M.J. Medrano, J. Aalmazán, M.J. Sierra, M.T. Olalla.
Situación Epidemiológica de las enfermedades cardiovasculares (I): mortalidad y morbilidad.
Bol Epidemiol Semanal, 6 (1998), pp. 149-153
[14.]
M.J. Medrano, G. López-Abente, M.J. Barrado, M. Pollán, J. Almazán.
Effect of age, birth cohort and period of death on cerebrovascular mortality in Spain, 1952 through 1991.
Stroke, 28 (1997), pp. 40-44
[15.]
J.R. Banegas, J.C. Alberdi, F. Rodriguez-Artalejo, V. Domínguez, J. Del Rey Calero.
Age-period-cohort analysis of mortality caused by ischemic cardiopathy in Spain 1965–1985.
Gac Sanit, 6 (1992), pp. 97-104
[16.]
G. Pérez, A. Pena, J. Sala, P. Roset, R. Masiá, J. Marrugat, et al.
Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990–1992.
Int J Epidemiol, 27 (1998), pp. 599-604
[17.]
H. Tunstall-Pedoe, K. Kuulasmaa, M. Mähönen, H. Tolonen, E. Ruokokoski, P. Amouyel.
Contribution of trends in survival and coronary events rates to changes in coronary heart disease mortality: 10 year results from 37 WHO MONICA Project populations (monitoring trends and determinants in cardiovascular disease).
Lancet, 353 (1999), pp. 1547-1557
[18.]
P.S. Sever, N.R. Poulter, B. Dahlof, H. Wedel, G. Beevers, M. Caulfield, on behalf of the ASCOT investigators, et al.
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial.
Journal of hypert, 19 (2001), pp. 1139-1147
[19.]
P.S. Sever, B. Dahlof, N.R. Poultre, H. Wedel, G. Beevers, M. Caulfield, et al.
Potential synergy between lipid-lowering and bloodpressure- lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Eur Heart J, 27 (2006), pp. 2982-2988
[20.]
P.S. Sever, B. Dahlof, N.R. Poultre, H. Wedel, G. Beevers, M. Caulfield, ASCOT investigators, et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcome trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial.
Lancet, 361 (2003), pp. 1149-1158
[21.]
Extended ASCOT-lipid lowering (ASCOT-LLA) study shows positive results of atorvastatin [leading article].
Cardiovasc J Afr, 19 (2008), pp. 49-51
[22.]
M. Brosa, R. Gisbert, J.M. Rodríguez, J. Soto.
Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario.
Pharmacoeconomics Spa Res Articl, 2 (2005), pp. 65-79
[23.]
D.A. Marshall, P.R. Douglas, M.F. Drummond, G.W. Torrance, S. Macleod, O. Manti, et al.
Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
Pharmacoeconomics, 26 (2008), pp. 477-495
[24.]
Prescribing information for Caduet. Pfizer SA
[25.]
J. Fernández de Bobadilla, C. Calvo, J.A. Gómez-Gerique, P. Lázaro, I. Méndez, M. Garcia Vargas, et al.
Coste por año de vida ganado con atorvastatina 10mg en pacientes hipertensos españoles en riesgo moderado: Evaluación económica del estudio ASCOT-LLA con costes españoles.
Pharmacoeconomics Spa Res Articl, 4 (2007), pp. 11-24
[26.]
Instituto Nacional de Estadística (INE). Proyecciones de población estimadas para la región (padrón municipal 1 enero de 2006) [accessed: January 15, 2009; http://www.ine.eswww.ine.es].
[27.]
J.R. Banegas Banegas.
Epidemiología de la hipertensión arterial en España Situación actual y perspectivas.
Hipertensión, 22 (2005), pp. 353-362
[28.]
V. Barrios, C. Escobar, J.L. Listerri, A. Calderón, E. Alegría, J. Muñiz, et al.
Control de presión arterial y lípidos y riesgo coronario en la población hipertensa asistida en Atención primaria en España Estudio PRESCOT.
Rev Clin Esp, 207 (2007), pp. 172-178
[29.]
R. Gabriel, R. Moreno, J. García-Puig, J.C. Abanades, R. Aristegui, J. Fernandez de Bobadilla.
The metabolic syndrome in the PALPITATES study (Prevalence of ASCOT-LIKE patient: Integral Territorial Assessment to obtain epidemiological data in Spain).
Atherosclerosis (Suppls.), 9 (2008), pp. 128
[30.]
J.L. Llisterri, G.C. Rodríguez, F.J. Alonso, J.R. Banegas, D. González-Segura, S. Lou, et al.
Control of blood pressure in Spanish hypertensive population attended in primary health-care PRESCAP 2006 study.
Med Clin (Barc), 130 (2008), pp. 681-687
[31.]
Base de datos del Consejo General de Colegios Farmacéuticos. Available from: http://www.portalfarma.com/home.nsf (accessed: January 15, 2009).
[32.]
A. Sicras Mainar, J. Fernández de Bobadilla, J. Rejas Gutiérrez, M. García Vargas.
Patrón de cumplimiento terapéutico de antihipertensivos y/o hipolipemiantes en pacientes hipertensos y/o dislipémicos en Atención Primaria.
An Med Interna, 23 (2006), pp. 1-14
[33.]
J. García del Pozo, E. Ramos Sevillano, F.J. De Abajo, R. Mateos Campos.
Utilización de antihipertensivos en españa (1995–2001).
Rev Esp Cardiol, 57 (2004), pp. 241-249
[34.]
Grupo de trabajo para el manejo de la hipertensión arterial de la European Society of Hipertensión (ESH) y la European Society of Cardiology (ESC).
Guía 2007 para el manejo de la Hipertensión.
J Hypertens, 25 (2007), pp. 1105-1187
[35.]
R. Jackson, C.M. Lawes, D.A. Bennett, R.J. Milne, A. Rodgers.
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk.
[36.]
B.V. Patel, R.S. Leslie, P. Thiebaud, M.B. Nichols, S.S. Tang, H. Solomon, et al.
Adherence with single-pill amlodipine/atorvastatin versus a two-pill regimen.
Vasc Health Risk Manag, 4 (2008), pp. 673-681
[37.]
F.D. Hobbs.
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin.
Vasc Health Risk Manag, 3 (2007), pp. 711-719
[38.]
N. Howell, R. Trotter, D.R. Mottram, P.H. Rowe.
Compliance with statins in primary care.
Pharm J, 272 (2004), pp. 223-226
[39.]
P. Tricoci, J.M. Allen, J.M. Kramer, R.M. Califf, S.C. Smith.
Scientific evidence underlying the ACC/AHA clinical practice guidelines.
JAMA, 301 (2009), pp. 831-841
[40.]
Sicras-Mainar A, Fernández de Bobadilla J, Navarro-Artieda R, Rejas-Gutiérrez J. Mortalidad por cualquier causa e incidencia de enfermedad cardiovascular en hipertensos con perfil ASCOT en un ámbito poblacional español. Aten Primaria. 2010.(APRIM-D-09-00241, in press).
Copyright © 2010. Sociedad Española de Farmacia Hospitalaria
Download PDF
Idiomas
Farmacia Hospitalaria
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.